文献速递心脑血管急症创伤与烧伤重症综合管理与镇静镇痛

左乙拉西坦与加巴喷丁联合治疗穿透性创伤性脑损伤诱发的非惊厥性癫痫

Combination therapy of levetiracetam and gabapentin against nonconvulsive seizures induced by penetrating traumatic brain injury.
PubMed 文献 · J Trauma Acute Care Surg · 2017-01-01
一句话结论大鼠穿透性弹道样脑损伤模型中,左乙拉西坦单药剂量依赖性减少非惊厥性癫痫发作,加巴喷丁单药亦有效,但两药联合未获额外获益且未达预期相加效应。

本研究在大鼠严重穿透性弹道样脑损伤(PBBI)模型中,评估左乙拉西坦(12.5–100.0 mg/kg)与加巴喷丁(1.25–25.0 mg/kg)单用或按固定剂量比联合经静脉注射每日两次共3天,连续脑电图监测72小时检测非惊厥性癫痫发作。左乙拉西坦(25–100 mg/kg)使发作频率降低44%–73%、持续时间缩短45%–64%;加巴喷丁(6.25–25 mg/kg)使频率降低61%–69%、持续时间缩短70%–78%。联合用药未产生额外获益,等辐射分析未达预期相加水平,提示在所试剂量比下两药对自发性创伤后癫痫发作不太可能产生有利相互作用。

要点

  • 大鼠PBBI模型中,左乙拉西坦25–100 mg/kg静脉注射每日两次使非惊厥性癫痫发作频率降低44%–73%、持续时间缩短45%–64%,呈剂量依赖性。
  • 加巴喷丁6.25–25 mg/kg静脉注射每日两次使发作频率降低61%–69%、持续时间缩短70%–78%,但三个最高剂量效应平台化。
  • 左乙拉西坦与加巴喷丁按固定剂量比联合给药未获额外获益,联合的剂量-反应曲线更接近左乙拉西坦单药。
  • 等辐射分析显示联合未达预期相加水平,提示所试剂量比下两药对自发性创伤后癫痫发作不太可能产生有利相互作用。
  • 本研究为首次将等辐射法用于自发性创伤后癫痫发作的抗癫痫药物联合治疗评估,作者认为该方法在评估直接与脑损伤相关的癫痫联合治疗中具有客观性。

适用人群与场景

  • 大鼠严重穿透性弹道样脑损伤(PBBI)模型,伤后连续脑电图监测72小时检测非惊厥性癫痫发作。

诊断标准与关键阈值

  • 以连续脑电图监测72小时检测PBBI诱发的非惊厥性癫痫发作。

处置流程与药物剂量

  • 左乙拉西坦12.5–100.0 mg/kg、加巴喷丁1.25–25.0 mg/kg,单用或按固定剂量比联合,静脉注射,每日两次,共3天。

研究设计与关键结果

  • 研究类型为大鼠PBBI模型剂量-反应研究;左乙拉西坦(25–100 mg/kg)使发作频率降低44%–73%、持续时间缩短45%–64%;加巴喷丁(6.25–25 mg/kg)使频率降低61%–69%、持续时间缩短70%–78%。
  • 左乙拉西坦呈剂量依赖性效应,加巴喷丁在三个最高剂量效应平台化;联合给药未获额外获益,联合曲线更接近左乙拉西坦单药。
  • 等辐射分析显示联合未达预期相加水平,提示所试剂量比下两药对自发性创伤后癫痫发作不太可能产生有利相互作用。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠PBBI模型剂量-反应研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,尽管左乙拉西坦与加巴喷丁联合未达相加效应,等辐射法在评估抗癫痫药物联合治疗直接与脑损伤相关的癫痫方面具有客观性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Posttraumatic seizures are a medical problem affecting patients with traumatic brain injury. Yet effective treatment is lacking owing to the limitations of antiepileptic drugs (AEDs) applicable to these patients.

METHODS: In this study, we evaluated the dose-response efficacy of levetiracetam (12.5-100.0 mg/kg) and gabapentin (1.25-25.0 mg/kg) administered either individually or in pairs at fixed-dose ratios as a combination in mitigating posttraumatic nonconvulsive seizures induced by severe penetrating ballistic-like brain injury (PBBI) in rats. Seizures were detected by continuous electroencephalogram (EEG) monitoring for 72 hours postinjury. Animals were treated twice per day for 3 days by intravenous injections.

RESULTS: Both levetiracetam (25-100 mg/kg) and gabapentin (6.25-25 mg/kg) significantly reduced PBBI-induced seizure frequency by 44% to 73% and 61% to 69%, and seizure duration by 45% to 64% and 70% to 78%, respectively. However, the two drugs manifested different dose-response profiles. Levetiracetam attenuated seizure activity in a dose-dependent fashion, whereas the beneficial effects of gabapentin plateaued across the three highest doses tested. Combined administration of levetiracetam and gabapentin mirrored the more classic dose-response profile of levetiracetam monotherapy. However, no additional benefit was derived from the addition of gabapentin. Furthermore, isobolographic analysis of the combination dose-response profile of levetiracetam and gabapentin failed to reach the expected level of additivity, suggesting an unlikelihood of favorable interactions between these two drugs against spontaneously occurring posttraumatic seizure activities at the particular set of dose ratios tested.

CONCLUSION: This study was the first attempt to apply isobolographic approach to studying AED combination therapy in the context of spontaneously occurring posttraumatic seizures. Despite the failure to achieve additivity from levetiracetam and gabapentin combination, it is important to recognize the objectivity of the isobolographic approach in the evaluation of AED combination therapy against seizures directly associated with brain injuries.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Lu XM, Cao Y, Mountney A, et al. Combination therapy of levetiracetam and gabapentin against nonconvulsive seizures induced by penetrating traumatic brain injury. J Trauma Acute Care Surg. 2017. PMID: 28452872. doi:10.1097/TA.0000000000001470

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。